Global S&T Development Trend Analysis Platform of Resources and Environment
DOI | 10.1038/s41467-017-02472-6 |
AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy | |
Bertran-Alamillo, Jordi1; Cattan, Valerie2; Schoumacher, Marie2; Codony-Servat, Jordi1; Gimenez-Capitan, Ana1; Cantero, Frederique2; Burbridge, Mike2; Rodriguez, Sonia1; Teixido, Cristina1,8; Roman, Ruth1; Castellvi, Josep1; Garcia-Roman, Silvia1; Codony-Servat, Carles1; Viteri, Santiago3; Cardona, Andres-Felipe4,5; Karachaliou, Niki3; Rosell, Rafael1,3,6,7; Molina-Vila, Miguel-Angel1 | |
2019-04-18 | |
发表期刊 | NATURE COMMUNICATIONS
![]() |
ISSN | 2041-1723 |
出版年 | 2019 |
卷号 | 10 |
文章类型 | Article |
语种 | 英语 |
国家 | Spain; France; Colombia |
英文摘要 | Non-small cell lung cancer (NSCLC) tumors harboring mutations in EGFR ultimately relapse to therapy with EGFR tyrosine kinase inhibitors (EGFR TKIs). Here, we show that resistant cells without the p.T790M or other acquired mutations are sensitive to the Aurora B (AURKB) inhibitors barasertib and S49076. Phospho-histone H3 (pH3), a major product of AURKB, is increased in most resistant cells and treatment with AURKB inhibitors reduces the levels of pH3, triggering G1/S arrest and polyploidy. Senescence is subsequently induced in cells with acquired mutations while, in their absence, polyploidy is followed by cell death. Finally, in NSCLC patients, pH3 levels are increased after progression on EGFR TKIs and high pH3 baseline correlates with shorter survival. Our results reveal that AURKB activation is associated with acquired resistance to EGFR TKIs, and that AURKB constitutes a potential target in NSCLC progressing to anti-EGFR therapy and not carrying resistance mutations. |
领域 | 资源环境 |
收录类别 | SCI-E |
WOS记录号 | WOS:000464979600006 |
WOS关键词 | AURORA-B-KINASE ; ONCOGENE-INDUCED SENESCENCE ; FACTOR RECEPTOR MUTATIONS ; MET/AXL/FGFR INHIBITOR ; 1ST-LINE TREATMENT ; GROWTH ARREST ; OPEN-LABEL ; GEFITINIB ; S49076 ; CHEMOTHERAPY |
WOS类目 | Multidisciplinary Sciences |
WOS研究方向 | Science & Technology - Other Topics |
URL | 查看原文 |
引用统计 | |
文献类型 | 期刊论文 |
条目标识符 | http://119.78.100.173/C666/handle/2XK7JSWQ/203628 |
专题 | 资源环境科学 |
作者单位 | 1.Quiron Dexeus Univ Hosp, Lab Oncol, Pangaea Oncol, Barcelona 08028, Spain; 2.Inst Rech Int Servier, F-92284 Suresnes, France; 3.Quiron Dexeus Univ Hosp, Inst Oncol Dr Rosell, Barcelona 08028, Spain; 4.Fdn Santa Fe Bogota, Clin & Translat Oncol Grp, Inst Oncol, Bogota 110111, Colombia; 5.Fdn Clin & Appl Canc Res FICMAC, Bogota 110111, Colombia; 6.Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Badalona 08916, Spain; 7.Hlth Sci Inst & Hosp, Germans Trias & Pujol, Campus Can Ruti, Badalona 08916, Spain; 8.Hosp Clin Barcelona, Serv Anat Patol, E-08036 Barcelona, Spain |
推荐引用方式 GB/T 7714 | Bertran-Alamillo, Jordi,Cattan, Valerie,Schoumacher, Marie,et al. AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy[J]. NATURE COMMUNICATIONS,2019,10. |
APA | Bertran-Alamillo, Jordi.,Cattan, Valerie.,Schoumacher, Marie.,Codony-Servat, Jordi.,Gimenez-Capitan, Ana.,...&Molina-Vila, Miguel-Angel.(2019).AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy.NATURE COMMUNICATIONS,10. |
MLA | Bertran-Alamillo, Jordi,et al."AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy".NATURE COMMUNICATIONS 10(2019). |
条目包含的文件 | 条目无相关文件。 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论